



ENROLLING NOW

The GALLOP Study for Geographic Atrophy

The purpose of the study is to find out if APL-3007, the drug that is being studied, dosed in combination with SYFOVRE®/pegcetacoplan (APL-2) is safe and effective in treating participants who have geographic atrophy associated with age-related macular degeneration (AMD).

You could help improve treatment for people like you with GA

Find Out More About the GALLOP Study

You may be eligible to participate in the GALLOP study if you:

- Are at least 60 years old
- Have been diagnosed with GA associated with AMD in one or both eyes
- Meet additional eligibility criteria assessed by your study physician

What Does Study Participation Involve?

- Participants will be randomly assigned to 1 of 2 doses of APL-3007 dosed in combination with SYFOVRE®/pegcetacoplan (APL-2) or placebo* dosed with SYFOVRE®/pegcetacoplan (APL-2)
- Participation in the study will last approximately 18 months, including 21 clinic visits that will last between 3 and 7 hours
- Visits will involve study related procedures including blood draws, eye examinations and other health related assessments to monitor the effectiveness of the treatment and participants general health

*A placebo is a substance that looks like the study drug but does not contain any active drug or ingredients. SYFOVRE®/pegcetacoplan (APL-2) has already been approved in the United States, for treatment of geographic atrophy associated with AMD.

What Else Should I Know?

- Participation is voluntary, and you can leave the study at any time
- There will be no charge for being in the study and all study tests not part of your usual geographic atrophy treatment will be provided at no cost
- Reasonable expenses related to clinic visits such as travel and food during visits may be reimbursed to you and/or your caregiver

Who can I Speak with about Study Participation?

To learn more about the GALLOP study please contact:

[Site Name and Phone Number]

The GALLOP Study is a Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with SYFOVRE®/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration.